Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.58 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | BPTF | Q12830 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.31 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19407334 | 0.93 | ACHE (0.50) | ACHEBCHEAPPNPC1KDM4E | |
| SCHEMBL17992288 | 0.75 | ACHE (0.66) | ACHEBCHEKDM4EALDH1A1MEN1 | |
| SCHEMBL19407545 | 0.74 | ACHE (0.37) | ACHE | |
| SCHEMBL17992287 | 0.74 | ACHE (1.00) | ACHEBCHEAPPKDM4EALDH1A1 | |
| SCHEMBL9584087 | 0.70 | ACHE (1.00) | ACHEBCHEAPPKDM4EALDH1A1 | |
| SCHEMBL19407388 | 0.70 | ACHE (0.34) | ACHE | |
| SCHEMBL2407199 | 0.64 | ACHE (0.37) | ACHE | |
| SCHEMBL2407668 | 0.63 | ACHE (0.36) | ACHE | |
| SCHEMBL2408242 | 0.63 | ACHE (0.38) | ACHEMAPK1 | |
| SCHEMBL21938559 | 0.63 | ACHE (0.45) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696635-B2 | Versatile ligand for palladium-catalyzed meta-C—H functionalizations of aromatic substrates | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-06-30 | — | — | US | disclosed |
| US-10611723-B2 | Ligand-enabled meta-C-H activation using a transient mediator | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190119212-A1 | A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS | THE SCRIPPS RESEARCH INSTITUTE | 2019-04-25 | — | — | US | disclosed |
| WO-2017184589-A1 | A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2016123361-A1 | LIGAND-ENABLED META-C-H ACTIVATION USING A TRANSIENT MEDIATOR | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10611723-B2 | Ligand-enabled meta-C-H activation using a transient mediator | HRH4, AHR, HRH3 | ACHE 659/4885BCHE 402/4885APP 3113/4885 |
| US-20190119212-A1 | A VERSATILE LIGAND FOR PALLADIUM-CATALYZED META-C-H FUNCTIONALIZATIONS | AHR, PAH, DOHH | ACHE 1129/4885BCHE 325/4885APP 2768/4885 |
| US-10696635-B2 | Versatile ligand for palladium-catalyzed meta-C—H functionalizations of aromatic substrates | PAH, AHR, DDC | ACHE 1260/4885BCHE 539/4885APP 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.